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Abstract
Backgroud: The underlying molecular and cellular mechanisms of radiation pneumonitis (RP) are
very complex. Several biological factors need to be considered together with the well known
dosimetric parameters for understanding the molecular events in developing RP in lung cancer
patients. The aim of this study was to correlate the variations of the cytokine levels in lung cancer
patients during radiation therapy (RT) with the occurrence of symptomatic RP.
Methods: Thirty-four lung cancer patients who received three-dimensional conformal radiation
therapy were evaluated prospectively. Serial blood samples before, at the beginning, in the middle
of, at the end of RT and 2 and 4 weeks after RT were analyzed for IL-1α, IL-6, IL-10, TNF-α and
TGF-β1 by performing enzyme-linked immunosorbent assay. The predictive values of dosimetric
factors for RP were evaluated, too.
Results: Overall, 8 patients (23.5%) had grade ≥ 2 RP. By serial measurement of cytokines level,
only the TGF-β1 level showed a correlation to the symptomatic RP. None of the other cytokines,
IL-1α, IL-6, IL-10 and TNF-α level was correlated with the risk of RP. The mean pretreatment TGF-
β1 level did not differ between RP and non-RP groups. However, during the period of radiation
treatment, the TGF-β1 level began to increase at the end of RT in the RP group and became
significantly higher 4 weeks after RT (p = 0.007). Using an ANOVA model for repeated-measures,
we found significant associations between the changes of TGF-β1 during the time course of the RT
and the risk of developing RP (p < 0.001). Most of the dosimetric factors showed a significant
association with RP.
Conclusion: Our results show that the changes of TGF-β1 could be correlated with RP and the
incorporation of the biological parameters into the dosimetric data could be useful for predicting
symptomatic RP.
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Background
Increasing radiation dose and combining it with chemo-
therapy were found to improve the local control for lung
cancer and thus improve the overall survival of lung can-
cer patients [1-4]. However, the tolerance of the surround-
ing normal tissues to radiation therapy limits the level of
dose that can be delivered for the treatment of lung can-
cer.
The risk of radiation pulmonary toxicity may increase for
the following patients: patients with a poor performance
status or inadequate pulmonary function, patients who
undergo combined chemoradiotherapy and patients
receiving an increased total radiation dose and treatment
volume. Dosimetric parameters such as V5, V10, V20,
V30, V40, the mean lung dose (MLD) and the normal tis-
sue complications probability (NTCP) have been reported
to be related with RP by several retrospective or prospec-
tive studies [5-11]. However, the underlying molecular
and cellular mechanisms of RP are very complex. Several
biological factors need to be considered together with the
above mentioned dosimetric parameters for understand-
ing the molecular events in developing radiation-induced
complications in normal tissue [5,8,12]. Several clinical
reports have suggested a possible role of profibrogenic
and proinflammatory cytokines in the modulation of
radiation pulmonary injury [12-18].
We designed a prospective study of lung cancer patients
who underwent radiation therapy to assess the value of
the cytokine dynamics, as well as of dosimetric factors, for
predicting the risk of developing symptomatic RP.
Methods
Patient eligibility
We prospectively included lung cancer patients who
underwent radiation therapy from November 2006 to
April 2007 at Seoul Saint Mary's Hospital, Seoul, Korea.
Patients eligible for this study were those who had histo-
logically proven lung cancer, received three-dimensional
conformal radiation therapy (3D-CRT) above 45 Gy and
an ECOG performance status score of 0-2 with the life
expectancy of more than 6 months. Written informed
consents were obtained from all of the patients in accord-
ance with the procedures of the Institutional Review
Board of the Hospital.
Clinical evaluation and treatment description
History taking and physical examination that emphasized
the respiratory system were performed before, during and
after RT. All of the patients underwent pretreatment chest
X-ray, chest CT scan, pulmonary function tests (PFT),
bone scan and if necessary, PET CT and brain MRI.
A chest CT scan including the entire lung volume was per-
formed with the immobilization device at 3 mm scan
thickness. The structures of interest, such as gross tumor
volume (GTV), clinical target volume (CTV), and normal
structures (esophagus, spinal cord, heart, and lung) were
defined and contoured on the multiple CT images. The
gross tumor volume included the tumor and clinically
involved nodes. GTV was determined by chest CT and/or
PET-CT. CTV included GTV with additional uniform 5 cm
expansion and ipsilateral hilar lymph nodes. The unin-
volved mediastinal, and supraclavicular nodal regions
were not routinely included in the CTV, but high risk
nodal stations near GTV nodes were included occasion-
ally. The PTV was obtained by a 0.7~1.0 cm margin 3-D
expansion from the CTV. An additional 0.5~1.0 cm mar-
gin was added to superior and inferior direction to
account for respiratory motion as assessed under fluoros-
copy. The beam arrangement was planned to minimize
the irradiated lung volume usually using 3 to 5 coplanar
oblique beams. Some patients of having bulky tumor
were treated with AP/PA fields to include the CTV for the
first 30~40 Gy, followed by off-cord oblique beam to the
GTV usually composed of 3~5 beams. After making cor-
rection for the tissue inhomogeneity using convolution/
superposition algorithm of the treatment planning system
(Pinnacle, Philips Medical System, Andover, MA, U.S.A.),
the mean lung dose (MLD), V5, V10, V20 and V30 (the
percentages of the irradiated lung volume receiving a radi-
ation dose exceeding 5 Gy, 10 Gy, 20 Gy and 30 Gy,
respectively) were calculated from the lung Dose Volume
Histogram (DVH). The lung dosimetric factors were calcu-
lated with subtraction of the GTV. The both lungs were
considered either as a single paired organ or as two sepa-
rate organs.
Radiation therapy was delivered with 10 MV X-ray from a
LINAC (Siemens, Concord, CA, U.S.A.). The median radi-
ation dose given was 55.6 Gy (range: 45-66 Gy) and the
median fraction size was 1.8 Gy (range: 1.8-3 Gy).
Follow up and the definition of RP
The patients visited the hospital for follow-up at 2 weeks
and 1, 2, 3 and 6 months after RT. Chest X-rays were per-
formed at every follow-up visit and chest CT was done at
1, 3 and 6 months after RT. We evaluated the symptoms
and signs of RP and the radiological changes upto at least
6 months after treatment. The end point of this study was
the development of ≥ grade 2 RP. Grading of the RP was
recorded using the scale defined by RTOG, which is based
on the severity of clinical symptoms of patients with radi-
ographic changes. It is outlined as follows: Grade 1 pneu-
monitis is for asymptomatic patients or who have mild
symptoms(dry coughing or dyspnea on exertion) with
radiographic findings; Grade 2 pneumonitis is for patientsRadiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
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who are moderately symptomatic(persistent coughing
requiring narcotic or antitussive); Grade 3 pneumonitis is
for severely symptomatic patients(severe coughing unre-
sponsive to narcotic or antitussive or dyspnea at rest,
intermittent oxygen or steroid required); Grade 4 pneu-
monitis is for patients with severe respiratory insufficiency
who needs continuous oxygen or assisted ventilation;
Grade 5 pneumonitis means death due to aggravation of
pneumonia. Lung injury in the immune suppressed host
is associated with diversity of etiologies: sepsis, respiratory
infection, irradiation, reperfusion injury, chemotherapeu-
tic agents and other drug reactions. Multidisciplinary
Team of Lung Cancer in Seoul St. Mary's Hospital
reviewed our patients suspected of having RP and
excluded other confirmed causes of pneumonia that mim-
icked RP such as infectious pneumonia or disease progres-
sion.
Analysis of the circulating cytokines
Peripheral blood samples were collected from the patients
at six points: before treatment and at the beginning, in the
middle of and at the end of RT and at 2 and 4 weeks after
the completion of RT. By using meticulous handling pro-
cedure, the blood samples were collected into an EDTA-
contained tube. Then within an hour, centrifugation at
3000 × g was carried out for 20 min at 4°C, the plasma
supernatant collected and stored in aliquots of 500 μL at -
80°C until use. The plasma IL-1α, IL-6, IL-10, TNF-α and
TGF-β1 levels were determined by an ELISA kit (R&D sys-
tems inc., Minneapolis, MN, U.S.A.). To minimize the var-
iability of each ELISA assay, we completed all of the assay
with just 2 times and compared standard dose density
curve of different assays to ensure reproducibility.
Statistical analysis
Statistical analysis was performed to correlate radiation
pneumonitis with various potentially predictive parame-
ters (dosimetric variables and changes in cytokine levels).
The differences in dosimetric variables and cytokine levels
between RP and non-RP groups were compared by con-
ducting the student's t-test. Analysis of variance for
repeated measures was used to examine the interaction
between changes of cytokine levels during time course
and RP occurrence. All the calculations were performed
using the SAS system (SAS Institute Inc., Cary, NC, USA).
A two-sided value of < 0.05 was considered statistically
significant.
Results
Patient Characteristics
Forty-three patients were initially included in the study,
but nine patients were then excluded from analysis due to
incomplete treatment (2 patients), unsatisfactory blood
sampling (3 patients) and follow-up loss or a follow-up
that was less than 6 months (4 patients).
For finally 34 evaluable patients, the histology was 14
squamous cell carcinomas, 6 adenocarcinomas, 11 small
cell carcinomas and 3 others. Twenty-five patients were
male and nine patients were female. The median patient
age was 63 (age range: 42-78). The ECOG performance
status was 0 or 1 for 29 patients (75%). Twenty-six
patients (78%) had a smoking history. Chemotherapy
was done before radiation in 21 patients (62%), and con-
current chemoradiotherapy was done in 15 patients
(44%). The used regimens for concurrent chemotherapy
were combinations of etoposide and cisplatin (6 patients)
or docetaxel and cisplatin (4 patients). Other chemother-
apeutic agents included weekly taxol (4 patients) or cispl-
atin (1 patient). Twelve patients (35.3%) had previous
surgery for the lung cancer. The results of the pretreatment
pulmonary function test for all the patients were as fol-
lows: the median FEV1 was 1.81 L (70%), the median
FEV1/FVC 67% and the median DLCO 78%. The patients
characteristics are summarized in Table 1.
Radiation pneumonitis
The median duration of follow up was 10 months (range:
1 - 23 months). Of the 34 patients who were included in
the study, 17 patients (50%) developed any grade of RP.
The severity of pneumonitis was grade 1 in 9 patients
(26.5%), grade 2 in 5 patients (14.7%) and grade 3 in 2
patients (5.9%). One patients (2.9%) died of aggravation
of RP. The median time to the onset of pneumonitis was
1.6 months (range: 0-3.3 months).
Among 8 patients who developed ≥2 RP, 7 patient
received concurrent chemoradiation. The most frequently
used regimens were combinations of etoposide and cispl-
atin (4 patients) or docetaxel and cisplatin (2 patients).
The patient who developed grade 5 pneumonitis was 74
year-old ex-smoker. He was newly diagnosed for squa-
mous cell carcinoma. The stage was IIIB, so concurrent
chemoradiation with weekly taxol was recommended
considering his good performance status (ECOG1) and
PFTs (FEV1 = 2.52L, DLCO = 84%). He was relatively well
tolerable until the end of treatment. However, he had
coughing, progressive dyspnea and fever with new devel-
oped consolidation corresponding to radiation field after
1.5 months completion of RT. No specific infectious cause
was identified. He received intravenous steroid therapy
and ventilator care, but died despite of 4 weeks of inten-
sive care.
Dosimetric parameters
All the dosimetric factors were analyzed for the lung both
as a paired organ and as a separate organ. Most of the dosi-
metric factors showed an association with RP. The data are
shown in Table 2. For the lung as a paired organ, V5, V10
and V20 were statistically significant factors for the occur-Radiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
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rence of RP (p = 0.035, p = 0.049, and p = 0.049, respec-
tively). The V30 and MLD were marginal significant (p =
0.068, p = 0.077). For the lung as a separate organ, the
MLD, V5, V10 and V20 values were statistically significant
factors for the occurrence of RP (p = 0.018, p = 0.003, p =
0.006 and p = 0.032, respectively). The V30 was margin-
ally significant (p = 0.053).
Serum cytokine levels
TGF- 1
As demonstrated in Table 3, the mean pretreatment TGF-
β1 level was 2.8 ± 0.8 × 104 pg/ml for the RP group and
2.3 ± 1.1 × 104 pg/ml for the non-RP group. The patients
who developed pneumonitis showed a higher level of pre-
treatment TGF-β1, but this was not statistically significant
(p = 0.157). During the period of radiation treatment,
from the beginning of RT to the middle of RT, the RP
group tended to show a decrease in the TGF-β1 level.
However, the TGF-β1 level began to increase at the end of
RT in the RP group and became significantly higher at 4
weeks after RT (p = 0.007). These elevation of TGF-β1 level
after RT were same in the patients of ≥ grade 2 RP (p =
0.062). However, TGF-β1 level of patients who did not
develop RP began to decrease relative to their pretreat-
ment level after middle of RT.
The pretreatment TGF-β1 level of the patient who died of
RP was relatively high (2.9 × 104 pg/ml). The TGF-β1 level
decreased during RT as same as other RP patients. His
TGF-β1 level at 4 weeks after RT was markedly increased
upto 4.2 × 104 pg/ml.
We performed an ANOVA model for repeated-measures
for analysis of chronological change in TGF-β1 level and
found that there were significant associations between the
changes of TGF-β1 level during the time course of radia-
tion and the risk of developing RP (p < 0.001 for develop-
ment of any grade of RP, p < 0.0001 for development of
grade ≥2 RP). These chronological changes in the serial
TGF-β1 levels are demonstrated in Table 4, Fig 1.
IL-6
The pretreatment IL-6 level was higher in the non-RP
group compared to the RP group (49.1 ± 123.3 pg/ml vs
Table 1: Patients characteristics (n = 34)
Characteristics Number of patients (%)
Gender Male 25 (74)
Female 9 (26)
Age(yrs) Median 63
Range 42~78
ECOG 0 13 (38)
1 16 (47)
2 5 (15)
Site Upper 22 (65)
Lower 10 (29)
Upper+Lower 2 (6)
Histology Sqamous cell ca 14 (41)
Adeno ca 6 (18)
Small cell ca 11 (32)
Other 3 (9)
Location Central 26 (76)
Peripheral 8 (24)
Previous surgery No 22 (65)
Yes 12 (35)
Previous chemotherapy No 13 (38)
Yes 21 (62)
Concurrent chemotherapy No 19 (56)
Yes 15 (44)
Smoking Never 7 (21)
Previous 13 (39
Current 13 (39)
PFTs FEV1(L) Median
Range
1.8
0.8~4.5
FEV1/FVC(%) Median
Range
67
34~94
DLCO(%) Median
Range
78
53~133
Abbreviations: ECOG, Eastern Cooperative Oncology Group Performance Scale; PFTs, Pulmonary Function TestsRadiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
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16.7 ± 23.9 pg/ml, respectively, p = 0.387). However, the
IL-6 level between each patient showed wide variation
compared to the TGF-β1 level, which showed a relatively
stable range of variation. The IL-6 level was low before
and during RT, but it began to increase after RT in both
groups. The changes of the IL-6 during the time course
were similar whether patients developed RP or not. Our
data showed a wide range of variation in the circulatory
IL-6 levels, but relatively little changes with the develop-
ment of RP.
Other cytokines
The IL-1α, IL-10 and TNF-α level were stable during the
whole course of RT and they were not correlated with the
risk of RP (data not shown).
Discussion
Being aware of the risk of radiation pulmonary injury is an
important aspect of patient management in the era of
combination of chemoradiation for treating lung cancer.
The recent studies on the new effective chemotherapeutic
agents or hyperfractionated RT have reported that the inci-
dence of grade ≥ 3 RP in patients who underwent concur-
rent chemoradiotherapy is between 21-23%[6,7]. Along
with combined chemotherapy, other patient-specific or
treatment-specific factors have been identified as predic-
tors of developing RP. However, currently, there are no
generally accepted methods available to accurately predict
an individual patient's risk of developing RT-induced pul-
monary morbidity. The purpose of this study was to assess
the values of the cytokine dynamics and dosimetric factors
to predict the risk of developing symptomatic RP.
The dose of irradiation administered to patients is distrib-
uted in a 3-D volume on the DVH. According to a litera-
ture review, dosimetric factors such as V5, V10, V20, V30,
Veff (effective volume) and MLD have statistically signifi-
cant correlation to symptomatic radiation pneumonitis
[9-11]. Also in the current study, most of the dosimetric
factors showed an association with RP. Because the lung
function may not be uniform across all regions of the
lung, it is unlikely that such a simplistic dose-volume rela-
Table 2: Dosimetric risk factors for development of RP ≥ grade 2
Mean ± SD
DVH parameters RP Non-RP p value*
Whole lung MLD (cGy) 1188 ± 354 957 ± 382 0.077
V5 (%) 58 ± 15 45 ± 12 0.035
V10 (%) 43 ± 13 34 ± 13 0.049
V20 (%) 29 ± 8 22 ± 11 0.049
V30 (%) 22 ± 7 17 ± 9 0.068
V40 (%) 15 ± 5 12 ± 7 0.299
Ipsilateral lung MLD (cGy) 1986 ± 491 1512 ± 612 0.018
V5 (%) 78 ± 13 63 ± 17 0.003
V10 (%) 67 ± 11 52 ± 19 0.006
V20 (%) 49 ± 11 38 ± 17 0.032
V30 (%) 38 ± 11 29 ± 15 0.053
V40 (%) 24 ± 9 22 ± 14 0.655
Abbreviations: RP, radiation pneumonitis; DVH, dose volume histogram; MLD, mean lung dose;
V5, the percentage of the irradiated lung volume receiving a radiation dose exceeding 5 Gy;
V10, the percentage of the irradiated lung volume receiving a radiation dose exceeding 10 Gy;
V20, the percentage of the irradiated lung volume receiving a radiation dose exceeding 20 Gy;
V30, the percentage of the irradiated lung volume receiving a radiation dose exceeding 30 Gy;
V40, the percentage of the irradiated lung volume receiving a radiation dose exceeding 40 Gy
* student's t-test
Table 3: Changes of mean TGF-β1 level during the course of 
radiation therapy
Mean ± SD (× 104 pg/ml)
Time RP Non-RP p value*
RP1 Before RT 2.8 ± 0.8 2.3 ± 1.1 0.157
(n = 17) Beginning of RT 2.4 ± 0.7 2.5 ± 1.1 0.738
Middle of RT 2.0 ± 0.6 2.4 ± 1.2 0.19
End of RT 2.1 ± 0.7 2.2 ± 0.9 0.879
2 wks after RT 2.1 ± 0.4 2.0 ± 0.8 0.806
4 wks after RT 2.8 ± 1.1 1.7 ± 0.5 0.007
RP2 Before RT 2.5 ± 1.0 2.6 ± 0.9 0.844
(n = 8) Beginning of RT 1.9 ± 0.6 2.6 ± 0.9 0.079
Middle of RT 1.8 ± 0.7 2.3 ± 0.9 0.168
End of RT 1.9 ± 0.6 2.2 ± 0.8 0.352
2 wks after RT 2.1 ± 0.7 2.0 ± 0.9 0.787
4 wks after RT 3.3 ± 1.7 2.0 ± 0.9 0.062
Abbreviations: RT, radiation therapy; wks, weeks; RP1, development 
of any grade of radiation pneumonitis; RP2, development of grade ≥ 2 
radiation pneumonitis;
* student's t-testRadiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
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tionship exists. However, these parameters are easy to cal-
culate and useful in the clinical setting.
Although dosimetric factors are important, these factors
don't take into consideration the molecular biological
events that may be responsible for radiation-induced
responses of normal tissue. Molecular events have been
shown to occur much earlier than the clinically apparent
radiation responses. Exposure to ionizing radiation rap-
idly triggers a cascade of genetic and molecular events,
which is an active process involving the production of a
number of inflammatory and fibrogenic cytokines by var-
ious cells in lung, for example, macrophages, epithelial
cells, endothelial cells, pneumocytes and fibroblasts.
These molecular processes are perpetuated beyond the
time point at which the acute insult has been removed.
Several recent studies have shown that cytokines (IL-1, IL-
6, IL-8, IL-10, TNF-α, platelet-derived growth factor and
TGF-β), surfactant apoproteins and cell adhesion mole-
cules (ICAM-1, E-selectin) have important roles in RT-
induced pulmonary injury [8,9,12-18]. A study of the
dynamics of the serum cytokines during the early course
of the treatment would be useful for predicting the risk of
pulmonary injury and for the early intervention of pneu-
monitis. Because these cytokines are thought to be key
mediators of lung toxicity, many of them have been exam-
ined as potential early markers for radiation pneumonitis.
Profibrogenic cytokine TGF-β1 is the most extensively
investigated among the various biological markers in radi-
ation-induced injuries. We observed that TGF-β1
decreased during RT and it began to increase at the end of
RT in the patients who developed RP. There have been
similar reported results for the TGF-β1 dynamics in rela-
tion to the development of pneumonitis after radiother-
apy for lung cancer. Hur et al. found that TGF-β1 was
decreased during RT and it was markedly increased at 2-4
weeks after the completion of RT for patients who devel-
oped symptomatic pneumonitis [14]. Kong et al. reported
that TGF-β1 decreased during RT in patients with an
increased pretreatment plasma TGF-β1 level, yet this
didn't normalize even by the completion of treat-
ment[19]. Other clinical studies have reported that the
absolute level or the relative ratio of the TGF-β1 level
showed meaningful changes during or after RT in patients
who suffered RP. However, the correlated time points
were different in each study and the patterns of the
changes were not always same [14,18-20]. We also evalu-
ated the TGF-β1 ratios (the ratios of a value from a partic-
ular time-point divided by the pre-RT value) presented in
table 5. In the patients who experienced grade ≥2 RP, the
TGF-β1 ratios tended to show a decrease than that of the
non-RP group, from the beginning of RT to the end of RT.
However, the TGF-β1 level began to increase at the 2
weeks after RT in the RP group and became more higher
at 4 weeks after RT (1.6 ± 1.0 vs 0.8 ± 0.3, p = 0.081). The
time point predictive of RP is different from the data of
Zhao et al which was 4 weeks during 6 weeks' course of RT
[20]. A recent report from Zhao et al suggests the combi-
nation of TGF-β1 and MLD may help stratify the patients
for their risk of RP to improve the predictive power [21].
Their data show the incidence of RP was 4.3% in patients
with a TGF-β1 ratio ≤ 1 and MLD ≤ 20 Gy, and 66.7% in
those with a TGF-β1 ratio ≥ 1 and MLD ≥ 20 Gy.
The TGF-β1 levels in bronchoalveolar lavage(BAL) fluid
from the irradiated area increased continuously during
and after RT compared to the pretreatment levels in the RP
group[17]. On the other hand, in several studies the pat-
tern of the changes of the TGF-β1 level was not distinct
between the RP and non-RP groups [12,15]. The reasons
for such conflicting results may be explained by the fact
that numerous factors can falsely increase TGF-β1 levels
and confound their predictive value for RP occurrence.
First, the tumor stroma may be responsible for the pro-
duction of TGF-β1 in lung cancer patients. The mean TGF-
Table 4: Results of repeated measures ANOVA about the changes of mean TGF-β1 level during the course of radiation therapy
Mean ± SD (× 104 pg/ml) Repeated measures ANOVA
Before RT Beginning of 
RT
Middle of RT End of RT 2 wks after RT 4 wks after RT Source F p value
RP1
(n = 17)
2.8 ± 0.8 2.4 ± 0.7 2.0 ± 0.6 2.1 ± 0.7 2.1 ± 0.4 2.8 ± 1.1 RP1 0.28 0.598
Non-RP
(n = 17)
2.3 ± 1.1 2.5 ± 1.1 2.4 ± 1.2 2.2 ± 0.9 2.0 ± 0.8 1.7 ± 0.5 time 2.36 0.043
time*RP1 4.79 0.001
RP2
(n = 8)
2.5 ± 1.0 1.9 ± 0.6 1.8 ± 0.7 1.9 ± 0.6 2.1 ± 0.7 3.3 ± 1.7 RP2 0.05 0.828
Non-RP 2.6 ± 0.9 2.6 ± 0.9 2.3 ± 0.9 2.2 ± 0.8 2.0 ± 0.9 2.0 ± 0.9 time 3.24 0.008
(n = 26) time*RP2 6.27 0.0001
Abbreviations: RT, radiation therapy; wks, weeks; RP1, development of any grade of radiation pneumonitis; RP2, development of grade ≥ 2 radiation 
pneumonitisRadiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
Page 7 of 9
(page number not for citation purposes)
β1 level in lung cancer patients was higher than that in the
normal controls (p < 0.001). According to a pathology
slide review, the degree of fibrosis that is present in tumor
is also significantly correlated with an elevated plasma
TGF-β1 level (p = 0.03). The dynamics of the plasma TGF-
β1 have been suggested to be a marker of RT-induced nor-
mal tissue injury as well as a marker of tumor response.
After radiotherapy, the patients who were alive with dis-
ease had significantly higher TGF-β1 levels than those
who were alive with no evidence of disease (p = 0.02) [19]
Second, careful handling of the sample is also important.
Variations of the centrifugation conditions and platelet
contamination could artificially elevate plasma TGF-β1
level[19,22]
IL-6 is a pleiotropic inflammatory cytokine that is impor-
tant in regulating immunologic and inflammatory
responses. IL-6 levels before, during and after thoracic RT
were significantly higher in those patients who developed
pneumonitis in several reports [13,23]. Especially Arpin et
al reported covariation of proinflammatory cytokine (IL-
6) and anti-inflammatory cytokine (IL-10) levels during
the first 2 week of RT were independent predictive evi-
dence of RP. However, other studies have failed to find a
relationship between IL-6 and the radiation-induced pul-
monary symptoms, like what our results have shown
[15,17]. In this study, the IL-6 level was low before and
during RT, but it began to increase after RT. These findings
are similar those of Chen et al [24]. However, the changes
of the IL-6 level were similar whether patients developed
RP or not. This suggests that the IL-6 produced by the lung
is not a major determinant of the circulating IL-6 levels.
The mean IL-6 concentrations were significantly higher in
the lung cancer patients than in the normal controls, and
the patients with metastatic tumor had higher IL-6 levels
than those patients with undisseminated disease, suggest-
ing that neoplastic cells may produce IL-6 [25]. IL-6 is an
acute phase inflammatory cytokine, and this would sug-
gest that the measurement of circulating IL-6 can reflect
the inflammatory state of the lung. The IL-6 levels fre-
quently increase in patients suffering with several pulmo-
nary diseases, including infectious pneumonia, interstitial
pneumonia and chronic obstructive pulmonary dis-
ease[17].
There are other potential biological predictors of RP, but
none has been conclusively demonstrated to identify the
patients who are at a high risk of radiation-induced pul-
monary toxicity [9,12,15,16]. Host-associated diseases,
the proportion of gross disease at the time of irradiation
and pre-RT treatment such as chemotherapy are all associ-
ated with local cytokine production [5,15]. The addition
of radiation on a background of subclinical damage may
augment a cytokine cascade and increase the severity of
acute and late side effects.
Although various cytokines are important in the patho-
genesis of radiation-induced pulmonary injury, our
results show that the changes of TGF-β1 could be an inde-
pendent predictor of developing RP and well correlated
with the time course of radiation therapy. However, the
role of cytokine markers in the cytokine cascades that pro-
mote pulmonary injury deserves further investigation.
Also, treatment strategies designed to block this patho-
logic process may need to be continued well beyond the
completion of RT.
Table 5: Changes of mean TGF-β1 ratio during the course of 
radiation therapy
Mean of Ratio ± SD
Time RP Non-RP p value*
RP2 Before RT
(n = 8) Beginning of RT 0.8 ± 0.2 1.0 ± 0.2 0.019
Middle of RT 0.8 ± 0.4 0.9 ± 0.4 0.238
End of RT 0.8 ± 0.2 0.9 ± 0.3 0.346
2 wks after RT 1.0 ± 0.6 0.9 ± 0.3 0.576
4 wks after RT 1.6 ± 1.0 0.8 ± 0.3 0.081
Abbreviations: RT, radiation therapy; wks, weeks; RP2, development 
of grade ≥ 2 radiation pneumonitis
* student's t-test
The pattern of the changes of the mean TGF-β1 level in the  RP group and the non-RP group Figure 1
The pattern of the changes of the mean TGF-β1 level 
in the RP group and the non-RP group. The TGF-β1 
level began to increase at the end of RT in the RP group and 
it became significantly higher at 4 weeks after RT (p = 0.007). 
However TGF-β1 level of patients who did not develop RP 
began to decrease relative to their pretreatment level after 
middle of RT. The solid line shows the mean level of TGF-β1 
in the RP group and the dashed line shows the mean level of 
TGF-β1 in the non-RP group. The data are presented as 
mean ± standard error of the mean.Radiation Oncology 2009, 4:59 http://www.ro-journal.com/content/4/1/59
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Conclusion
Although the current study had a limited number of
patients, we demonstrated that, in the patients who devel-
oped RP, the TGF-β1 level decreased during RT and began
to increase at the end of RT. And the TGF-β1 level at 4
weeks after RT was significantly higher than the TGF-β1
level of the patients who didn't develop RP. TGF-β1 may
contribute to the process leading to a radiation injury in
human lung tissue. While the change of TGF-β1 level did
not take place early in time course of RT with having a pre-
dictive value in our study, the incorporation of the biolog-
ical parameters into the dosimetric data that have been
developed to predict radiation-induced lung injury may
improve the predictive accuracy. Further research must
continue to identify biomarkers that will one day allow us
to tailor our therapies in response to the highly accurate
predictions of risk for the development of radiation pneu-
monitis.
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